February 2018

The Life Sciences Industry of Tomorrow: Healthy Canadians, Healthy Future

11:30am-1:30pm | Fairmont Royal York - 100 Front Street West, Toronto, Toronto

The life sciences are innovating at an unprecedented pace, is government policy keeping up or holding us back?

Whether it’s artificial intelligence or new gene therapies that can potentially cure cancer, we are at a pivotal moment in the evolution and adoption of new technologies that will fundamentally change how we live, work, and treat illness. Access to these breakthrough technologies is key to our future health and prosperity and Canadians at the cutting edge of many of these new discoveries expect no less. But as Pamela Fralick, President of Innovative Medicines Canada explains, proposed policy changes to Canada’s patented drug pricing regime will have profound implications for Canadian healthcare and life sciences for decades to come.

- Lunch will be served -

Member price:
Individual seat: $89 +HST
Table (seats 10): $800 +HST

Regular price:
Individual seat: $110 +HST
Table (seats 10): $990 +HST

- For information about accessibility, please email dickinson@economicclub.ca
- Dietary restriction notes and meal requests must be submitted to dickinson@economicclub.ca by Friday, February 2, 2018.

*The views expressed on the Economic Club platform are not that of the Economic Club or its affiliates but of the speakers alone and the organizations they represent*

Brian Hilberdink

Novo Nordisk Canada Inc.

Brian Hilberdink

Brian Hilberdink is the President of Novo Nordisk Canada. His 22-year career includes several years at the company’s headquarters in Denmark in the Global Marketing organisation, in addition to a variety of roles with Novo Nordisk in the U.S. Brian is an active contributor on the Board of Innovative Medicines Canada and BIOTECanada, and is also a founding member of the Diabetes Canada Impact Council.

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given it experience and capabilities that also enable it to help people defeat obesity, hemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries, and markets its products in more than 170 countries.

Janet Yale

President & CEO
The Arthritis Society of Canada

Janet Yale

Janet Yale is the president and CEO of The Arthritis Society (Canada). Janet previously served as executive vice president at TELUS, and president and CEO of the Canadian Cable Television Association, along with other c-suite roles in private, public and not -for-profit organizations.

Currently Janet chairs the Arthritis Alliance of Canada, Past-Chair of the Ontario Trillium Foundation, and serves on the boards of Samara and the Ottawa Art Gallery. Janet is a recipient of the Queen Elizabeth II Diamond Jubilee Medal.

Jason Field, Ph.D.

President & CEO
Life Sciences Ontario

Jason Field, Ph.D.

Dr. Jason Field is the President and CEO of Life Sciences Ontario (LSO), the industry voice for the life sciences sector in Ontario. LSO is a member-driven organization that represents and promotes the province's vibrant and diverse life sciences sector. LSO collaborates with governments, academia, industry and other life science organizations in Ontario and across Canada to promote and encourage commercial success throughout this diverse sector. Jason obtained his PhD in Chemistry from the University of Massachusetts and his undergraduate degree from the University of Waterloo. Following graduate school, Jason returned to Ontario and worked in the pharmaceutical industry as a research scientist developing scalable manufacturing processes of active pharmaceutical ingredients. In 2007, he joined the Ministry of Economic Development and Trade (MEDT) where he led a team of senior advisors dedicated to growing Ontario's life sciences and information and communication technologies (ICT) sectors. During his time at MEDT, Jason was integral to the development of a number of strategic policy initiatives and spearheaded negotiations with several major ICT and life sciences companies that resulted in significant new investments in the province. Jason joined LSO as Executive Director in October, 2011 and was appointed as President and CEO in April, 2014.

Pamela Fralick

Innovative Medicines Canada

Pamela Fralick

Driven by a life-long commitment to improving Canadians’ health and well-being, Pamela works with the country’s research-based pharmaceutical companies to ensure that all Canadians have access to the medicines they need, when they need them, and that Canada remains an attractive place to invest in the life sciences. Her unique perspective on the policy issues of the day is informed by her decades of working closely with patients and researchers to find solutions to some of our most pressing healthcare challenges.
Prior to IMC, Pamela was President and CEO of the Canadian Cancer Society, where she led the transformation of the organization’s operational and governance structures, helping to strengthen its position as the country’s leading cancer-fighting charity.
Her patient-centric perspective is also shaped by past leadership roles at the Canadian Healthcare Association (now HealthCareCAN), the Canadian Physiotherapy Association, the Health Action Lobby (HEAL), the Health Charities Coalition of Canada (HCCC), CAMH (Centre for Addiction and Mental Health) and the Canadian Centre on Substance Abuse.

Wayne Critchley

Former Executive Director, PMPRB

Wayne Critchley

Wayne Critchley is Senior Associate with Global Public Affairs' Health & Life Sciences practice, providing counsel to leading biopharmaceutical and medical device corporations and associations along with other health policy stakeholders.

Wayne has a long track record of success as a senior executive with over twenty years of experience in government departments, boards and agencies dealing primarily with issues that impact the pharmaceutical sector. He served as Executive Director of the Patented Medicine Prices Review Board from 1990 to 2005 and as a Vice President of the Canadian Agency for Drugs and Technologies in Health in 2009. Prior to 1990, Wayne occupied several senior positions in the Competition Bureau.

His private sector experience includes providing high impact strategic advice and counsel to the innovative life sciences sector as a partner in one of Canada's leading law firms and he is widely recognized as an expert in pharmaceutical pricing, reimbursement and market access. Wayne is regularly called upon to write and present on Canadian pharmaceutical issues.

Wayne serves on the Board of Directors of the Canadian Organization for Rare Disorders. He is also a member of the Board of Directors of the Canadian Club of Ottawa and was President from 2012-2013.

Our Sponsors

Telus Interac Green Shield Canada